Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Arbovirus surveillance: first dengue virus detection in local Aedes albopictus mosquitoes in Europe, Catalonia, Spain, 2015.

Aranda C, Martínez MJ, Montalvo T, Eritja R, Navero-Castillejos J, Herreros E, Marqués E, Escosa R, Corbella I, Bigas E, Picart L, Jané M, Barrabeig I, Torner N, Talavera S, Vázquez A, Sánchez-Seco MP, Busquets N.

Euro Surveill. 2018 Nov;23(47). doi: 10.2807/1560-7917.ES.2018.23.47.1700837.

2.

Erratum for Brunschwig et al., "UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria".

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Gonzàlez Cabrera D, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01941-18. doi: 10.1128/AAC.01941-18. Print 2018 Nov. No abstract available.

3.

A high throughput screen for next-generation leads targeting malaria parasite transmission.

Delves MJ, Miguel-Blanco C, Matthews H, Molina I, Ruecker A, Yahiya S, Straschil U, Abraham M, León ML, Fischer OJ, Rueda-Zubiaurre A, Brandt JR, Cortés Á, Barnard A, Fuchter MJ, Calderón F, Winzeler EA, Sinden RE, Herreros E, Gamo FJ, Baum J.

Nat Commun. 2018 Sep 18;9(1):3805. doi: 10.1038/s41467-018-05777-2.

4.

Gametocytes from K13 Propeller Mutant Plasmodium falciparum Clinical Isolates Demonstrate Reduced Susceptibility to Dihydroartemisinin in the Male Gamete Exflagellation Inhibition Assay.

Lozano S, Gamallo P, González-Cortés C, Presa Matilla JL, Fairhurst RM, Herreros E, Amaratunga C, Rodrigues J.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01426-18. doi: 10.1128/AAC.01426-18. Print 2018 Dec.

5.

UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT, de Kock C, Wiesner L, Denti P, Waterson D, Blasco B, Leroy D, Witty MJ, Donini C, Duffy J, Wittlin S, White KL, Charman SA, Jiménez-Díaz MB, Angulo-Barturen I, Herreros E, Gamo FJ, Rochford R, Mancama D, Coetzer TL, van der Watt ME, Reader J, Birkholtz LM, Marsh KC, Solapure SM, Burke JE, McPhail JA, Vanaerschot M, Fidock DA, Fish PV, Siegl P, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Silue KD, Street LJ, Chibale K.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00012-18. doi: 10.1128/AAC.00012-18. Print 2018 Sep. Erratum in: Antimicrob Agents Chemother. 2018 Oct 24;62(11):.

PMID:
29941635
6.

Synthesis and Structure-Activity Relationships of the Novel Antimalarials 5-Pyridinyl-4(1 H)-Pyridones.

Bueno JM, Calderon F, Chicharro J, De la Rosa JC, Díaz B, Fernández J, Fiandor JM, Fraile MT, García M, Herreros E, García-Pérez A, Lorenzo M, Mallo A, Puente M, Saadeddin A, Ferrer S, Angulo-Barturen I, Burrows JN, León ML.

J Med Chem. 2018 Apr 26;61(8):3422-3435. doi: 10.1021/acs.jmedchem.7b01256. Epub 2018 Apr 5.

PMID:
29589932
7.

Potent Plasmodium falciparum gametocytocidal compounds identified by exploring the kinase inhibitor chemical space for dual active antimalarials.

van der Watt ME, Reader J, Churchyard A, Nondaba SH, Lauterbach SB, Niemand J, Abayomi S, van Biljon RA, Connacher JI, van Wyk RDJ, Le Manach C, Paquet T, González Cabrera D, Brunschwig C, Theron A, Lozano-Arias S, Rodrigues JFI, Herreros E, Leroy D, Duffy J, Street LJ, Chibale K, Mancama D, Coetzer TL, Birkholtz LM.

J Antimicrob Chemother. 2018 May 1;73(5):1279-1290. doi: 10.1093/jac/dky008.

PMID:
29420756
8.

A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.

O'Neill PM, Amewu RK, Charman SA, Sabbani S, Gnädig NF, Straimer J, Fidock DA, Shore ER, Roberts NL, Wong MH, Hong WD, Pidathala C, Riley C, Murphy B, Aljayyoussi G, Gamo FJ, Sanz L, Rodrigues J, Cortes CG, Herreros E, Angulo-Barturén I, Jiménez-Díaz MB, Bazaga SF, Martínez-Martínez MS, Campo B, Sharma R, Ryan E, Shackleford DM, Campbell S, Smith DA, Wirjanata G, Noviyanti R, Price RN, Marfurt J, Palmer MJ, Copple IM, Mercer AE, Ruecker A, Delves MJ, Sinden RE, Siegl P, Davies J, Rochford R, Kocken CHM, Zeeman AM, Nixon GL, Biagini GA, Ward SA.

Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.

9.

Hundreds of dual-stage antimalarial molecules discovered by a functional gametocyte screen.

Miguel-Blanco C, Molina I, Bardera AI, Díaz B, de Las Heras L, Lozano S, González C, Rodrigues J, Delves MJ, Ruecker A, Colmenarejo G, Viera S, Martínez-Martínez MS, Fernández E, Baum J, Sinden RE, Herreros E.

Nat Commun. 2017 May 17;8:15160. doi: 10.1038/ncomms15160.

10.

A novel validated assay to support the discovery of new anti-malarial gametocytocidal agents.

Bahamontes-Rosa N, Gomez-Lorenzo MG, Lelièvre J, Rodriguez Alejandre A, Almela MJ, Lozano S, Herreros E, Gamo FJ.

Malar J. 2016 Jul 22;15(1):385. doi: 10.1186/s12936-016-1429-9.

11.

Transmission-Blocking Potential of MEFAS, a Hybrid Compound Derived from Artesunate and Mefloquine.

Penna-Coutinho J, Almela MJ, Miguel-Blanco C, Herreros E, Sá PM, Boechat N, Krettli AU.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3145-7. doi: 10.1128/AAC.02216-15. Print 2016 May.

12.

A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery.

Almela MJ, Lozano S, Lelièvre J, Colmenarejo G, Coterón JM, Rodrigues J, Gonzalez C, Herreros E.

PLoS One. 2015 Aug 28;10(8):e0135139. doi: 10.1371/journal.pone.0135139. eCollection 2015.

13.

Imaging-based high-throughput screening assay to identify new molecules with transmission-blocking potential against Plasmodium falciparum female gamete formation.

Miguel-Blanco C, Lelièvre J, Delves MJ, Bardera AI, Presa JL, López-Barragán MJ, Ruecker A, Marques S, Sinden RE, Herreros E.

Antimicrob Agents Chemother. 2015;59(6):3298-305. doi: 10.1128/AAC.04684-14. Epub 2015 Mar 23.

14.

Advances in nanomedicine towards clinical application in oncology and immunology.

Herreros E, Morales S, Cortés C, Cabaña M, Peñaloza JP, Jara L, Geraldo D, Otero C, Fernández-Ramires R.

Curr Pharm Biotechnol. 2014;15(9):864-79. Review.

PMID:
25213311
15.

Red blood cells derived from peripheral blood and bone marrow CD34⁺ human haematopoietic stem cells are permissive to Plasmodium parasites infection.

Fernandez-Becerra C, Lelievre J, Ferrer M, Anton N, Thomson R, Peligero C, Almela MJ, Lacerda MV, Herreros E, Del Portillo HA.

Mem Inst Oswaldo Cruz. 2013 Sep;108(6):801-3. doi: 10.1590/0074-0276108062013019.

16.

Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs.

Delves MJ, Ruecker A, Straschil U, Lelièvre J, Marques S, López-Barragán MJ, Herreros E, Sinden RE.

Antimicrob Agents Chemother. 2013 Jul;57(7):3268-74. doi: 10.1128/AAC.00325-13. Epub 2013 Apr 29.

17.

Quinolone-3-diarylethers: a new class of antimalarial drug.

Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CHM, Price RN, Avery VM, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK.

Sci Transl Med. 2013 Mar 20;5(177):177ra37. doi: 10.1126/scitranslmed.3005029.

18.

Exploration of 4(1H)-pyridones as a novel family of potent antimalarial inhibitors of the plasmodial cytochrome bc1.

Bueno JM, Herreros E, Angulo-Barturen I, Ferrer S, Fiandor JM, Gamo FJ, Gargallo-Viola D, Derimanov G.

Future Med Chem. 2012 Dec;4(18):2311-23. doi: 10.4155/fmc.12.177. Review.

PMID:
23234553
19.

Comparison and Optimization of Different Methods for the In Vitro Production of Plasmodium falciparum Gametocytes.

Roncalés M, Vidal-Mas J, Leroy D, Herreros E.

J Parasitol Res. 2012;2012:927148. doi: 10.1155/2012/927148. Epub 2012 Mar 15.

20.

Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay.

Lelièvre J, Almela MJ, Lozano S, Miguel C, Franco V, Leroy D, Herreros E.

PLoS One. 2012;7(4):e35019. doi: 10.1371/journal.pone.0035019. Epub 2012 Apr 13.

21.

Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides.

Pešić D, Starčević K, Toplak A, Herreros E, Vidal J, Almela MJ, Jelić D, Alihodžić S, Spaventi R, Perić M.

J Med Chem. 2012 Apr 12;55(7):3216-27. doi: 10.1021/jm201676t. Epub 2012 Mar 23.

PMID:
22380766
22.

Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents.

Starčević K, Pešić D, Toplak A, Landek G, Alihodžić S, Herreros E, Ferrer S, Spaventi R, Perić M.

Eur J Med Chem. 2012 Mar;49:365-78. doi: 10.1016/j.ejmech.2012.01.039. Epub 2012 Jan 26.

PMID:
22321992
23.

Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen.

Sanz LM, Jiménez-Díaz MB, Crespo B, De-Cozar C, Almela MJ, Angulo-Barturen I, Castañeda P, Ibañez J, Fernández EP, Ferrer S, Herreros E, Lozano S, Martínez MS, Rueda L, Burrows JN, García-Bustos JF, Gamo FJ.

Antimicrob Agents Chemother. 2011 Dec;55(12):5740-5. doi: 10.1128/AAC.05188-11. Epub 2011 Oct 3.

24.

Potent antimalarial 4-pyridones with improved physico-chemical properties.

Bueno JM, Manzano P, García MC, Chicharro J, Puente M, Lorenzo M, García A, Ferrer S, Gómez RM, Fraile MT, Lavandera JL, Fiandor JM, Vidal J, Herreros E, Gargallo-Viola D.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5214-8. doi: 10.1016/j.bmcl.2011.07.044. Epub 2011 Jul 23. Erratum in: Bioorg Med Chem Lett. 2013 Dec 15;23(24):6938.

PMID:
21824778
25.

Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.

Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, Guinovart C, Bassat Q, Renom M, Puyol L, Macete E, Herreros E, Leach A, Dubois MC, Demoitie MA, Lievens M, Vekemans J, Loucq C, Ballou WR, Cohen J, Alonso PL.

Vaccine. 2011 Aug 11;29(35):6059-67. doi: 10.1016/j.vaccine.2011.03.041. Epub 2011 Apr 7.

PMID:
21443960
26.

Activation of geminivirus V-sense promoters in roots is restricted to nematode feeding sites.

Escobar C, García A, Aristizábal F, Portillo M, Herreros E, Munoz-Martín MA, Grundler F, Mullineaux PM, Fenoll C.

Mol Plant Pathol. 2010 May;11(3):409-17. doi: 10.1111/j.1364-3703.2010.00611.x.

PMID:
20447288
27.

Characterization of the phospholipidogenic potential of 4(1H)-pyridone antimalarial derivatives.

Almela MJ, Torres PA, Lozano S, Herreros E.

Toxicol In Vitro. 2009 Dec;23(8):1528-34. doi: 10.1016/j.tiv.2009.06.015. Epub 2009 Jun 18.

PMID:
19540329
28.

Effect of the haematocrit layer geometry on Plasmodium falciparum static thin-layer in vitro cultures.

Ferrer J, Rosal MD, Vidal JM, Prats C, Valls J, Herreros EA, López D, Gargallo D.

Malar J. 2008 Oct 8;7:203. doi: 10.1186/1475-2875-7-203.

29.

A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes.

Angulo-Barturen I, Jiménez-Díaz MB, Mulet T, Rullas J, Herreros E, Ferrer S, Jiménez E, Mendoza A, Regadera J, Rosenthal PJ, Bathurst I, Pompliano DL, Gómez de las Heras F, Gargallo-Viola D.

PLoS One. 2008 May 21;3(5):e2252. doi: 10.1371/journal.pone.0002252.

30.

Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.

Yeates CL, Batchelor JF, Capon EC, Cheesman NJ, Fry M, Hudson AT, Pudney M, Trimming H, Woolven J, Bueno JM, Chicharro J, Fernández E, Fiandor JM, Gargallo-Viola D, Gómez de las Heras F, Herreros E, León ML.

J Med Chem. 2008 May 8;51(9):2845-52. doi: 10.1021/jm0705760. Epub 2008 Apr 9.

PMID:
18396855
31.

Individual-based model and simulation of Plasmodium falciparum infected erythrocyte in vitro cultures.

Ferrer J, Vidal J, Prats C, Valls J, Herreros E, Lopez D, Giró A, Gargallo D.

J Theor Biol. 2007 Oct 7;248(3):448-59. Epub 2007 Jun 2.

PMID:
17632129
32.

Evaluation of N-(phenylmethyl)-4-[5-(phenylmethyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-4-yl]benzamide inhibitors of Mycobacterium tuberculosis growth.

Wall MD, Oshin M, Chung GA, Parkhouse T, Gore A, Herreros E, Cox B, Duncan K, Evans B, Everett M, Mendoza A.

Bioorg Med Chem Lett. 2007 May 15;17(10):2740-4. Epub 2007 Mar 3.

PMID:
17418567
33.

[Cell saver devices in coronary revascularization surgery without extracorporeal circulation reduce transfusion requirements].

Ysasi A, Trujillo MJ, Tuesta ID, Llorens R, Herreros E.

Rev Esp Anestesiol Reanim. 2006 Oct;53(8):465-70. Spanish.

PMID:
17125011
34.

Regulation of MSV and WDV virion-sense promoters by WDV nonstructural proteins: a role for their retinoblastoma protein-binding motifs.

Muñoz-Martín A, Collin S, Herreros E, Mullineaux PM, Fernández-Lobato M, Fenoll C.

Virology. 2003 Feb 15;306(2):313-23.

35.

Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole.

Rossello A, Bertini S, Lapucci A, Macchia M, Martinelli A, Rapposelli S, Herreros E, Macchia B.

J Med Chem. 2002 Oct 24;45(22):4903-12.

PMID:
12383016
36.

Antifungal activities and cytotoxicity studies of six new azasordarins.

Herreros E, Almela MJ, Lozano S, Gomez de las Heras F, Gargallo-Viola D.

Antimicrob Agents Chemother. 2001 Nov;45(11):3132-9.

37.

Development of a high throughput in vitro toxicity screen predictive of high acute in vivo toxic potential.

Evans SM, Casartelli A, Herreros E, Minnick DT, Day C, George E, Westmoreland C.

Toxicol In Vitro. 2001 Aug-Oct;15(4-5):579-84.

PMID:
11566594
38.

In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.

Aviles P, Aliouat EM, Martinez A, Dei-Cas E, Herreros E, Dujardin L, Gargallo-Viola D.

Antimicrob Agents Chemother. 2000 May;44(5):1284-90.

39.

Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi.

Herreros E, Martinez CM, Almela MJ, Marriott MS, De Las Heras FG, Gargallo-Viola D.

Antimicrob Agents Chemother. 1998 Nov;42(11):2863-9.

40.

Evaluation of drug efficacy by using animal models or in vitro systems.

Brun Pascaud M, Herreros E, Aliouat EM, Dei-Cas E.

FEMS Immunol Med Microbiol. 1998 Sep;22(1-2):173-9. Review.

41.

Microplate assays for in vitro evaluation of anti-Pneumocystis drugs.

Herreros E, Almela MJ, Martinez M, Lozano S, Jackson H, Aliouat EM, Gargallo-Viola D.

J Eukaryot Microbiol. 1997 Nov-Dec;44(6):43S-44S. No abstract available.

PMID:
9508430
42.

A reorganized Candida albicans DNA sequence promoting homologous non-integrative genetic transformation.

Herreros E, García-Sáez MI, Nombela C, Sánchez M.

Mol Microbiol. 1992 Dec;6(23):3567-74.

PMID:
1474898
43.

Fungal enzymes in the pathogenesis of fungal infections.

Ogawa H, Nozawa Y, Rojanavanich V, Tsuboi R, Yoshiike T, Banno Y, Takahashi M, Nombela C, Herreros E, Garcia-Saez MI, et al.

J Med Vet Mycol. 1992;30 Suppl 1:189-96. Review. No abstract available.

PMID:
1474443
44.

[Modified Thal's gastroesophagoplasty for the treatment of megaesophagus].

Sader AA, Carneiro JJ, Brasil JC, Ribeiro PJ, Herreros E.

AMB Rev Assoc Med Bras. 1975 Mar;21(3):72-6. Portuguese. No abstract available.

PMID:
1079613
45.

[Heal... and be healed; therapy in retrospect].

HERREROS E.

Medicamenta (Madr). 1950 Nov 20;8(191):357-8. Undetermined Language. No abstract available.

PMID:
14805756

Supplemental Content

Loading ...
Support Center